Britta Hochsmann

Ulm, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Eltrombopag plus cyclosporine A for moderate aplastic anemia (EMAA): a placebo-controlled, double-blind, phase 3 trial.

Eltrombopag plus cyclosporine A for moderate aplastic anemia (EMAA): a placebo-controlled, double-blind, phase 3 trial.

Journal: Blood

Published: January 23, 2026

Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy.

Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy.

Journal: Blood advances

Published: December 01, 2025

Ravulizumab for Treatment of Paroxysmal Nocturnal Hemoglobinuria During Pregnancy.

Ravulizumab for Treatment of Paroxysmal Nocturnal Hemoglobinuria During Pregnancy.

Journal: Blood advances

Published: December 01, 2025

Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan.

Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan.

Journal: Advances in therapy

Published: April 18, 2025

Cellular expression of PD-1, PD-L1 and CTLA-4 in patients with JAK2V617F mutated myeloproliferative disorders.

Cellular expression of PD-1, PD-L1 and CTLA-4 in patients with JAK2V617F mutated myeloproliferative disorders.

Journal: Clinical chemistry and laboratory medicine

Published: March 13, 2025

Patient characteristics and clinical determinants of outpatient red cell transfusions.

Patient characteristics and clinical determinants of outpatient red cell transfusions.

Journal: Transfusion

Published: January 31, 2025

Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.

Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.

Journal: The Lancet. Haematology

Published: January 13, 2025

Late-onset telomere biology disorders in adults: clinical insights and treatment outcomes from a retrospective registry cohort.

Late-onset telomere biology disorders in adults: clinical insights and treatment outcomes from a retrospective registry cohort.

Journal: Blood advances

Published: September 04, 2024

The complement model disease paroxysmal nocturnal hemoglobinuria.

The complement model disease paroxysmal nocturnal hemoglobinuria.

Journal: European journal of immunology

Published: April 02, 2024

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.

Journal: The New England journal of medicine

Published: March 13, 2024

Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment.

Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment.

Journal: Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Published: March 04, 2024

Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways.

Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways.

Journal: The Journal of biological chemistry

Published: July 26, 2023

Showing 1-12 of 61

Last Updated: 09/26/2026